 Checkpoint Therapeutics, Inc. Checkpoint CKPT, a clinical-stage immunotherapy and targeted oncology company, today announced that feedback from the U.S. Food and Drug Administration FDA has confirmed the companys plan to submit cosibelimab for full approval as a treatment for patients with metastatic cutaneous squamous cell carcinoma CSCC based on efficacy and safety data from the ongoing open-label, multicenter, Phase 1 clinical trial, Study CK-301-101 NCT03212404. This registration-enabling clinical trial is currently enrolling a cohort of patients with metastatic CSCC, with a target enrollment of approximately 75 to 100 patients and a primary efficacy endpoint of confirmed objective response rate ORR assessed by independent central review. 